

# Company Heartbeats

**Swiss companies** - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
06 Aug 25	u-blox	Semi-annual report	CHF 108.20	Call	<a href="#">S2ABCU</a>	19 Dec 25	4.76	120.00	0.30	<a href="#">Calls on u-blox</a>
07 Aug 25	Swisscom	Semi-annual report	CHF 577.50	Call	<a href="#">SUB3OU</a>	19 Dec 25	16.36	600.00	0.12	<a href="#">Calls on Swisscom</a>
				Put	<a href="#">SKZBSU</a>	19 Dec 25	14.03	560.00	0.14	<a href="#">Puts on Swisscom</a>
07 Aug 25	Sandoz	Semi-annual report	CHF 46.29	Call	<a href="#">BGRSYU</a>	19 Dec 25	7.66	48.00	0.26	<a href="#">Calls on Sandoz</a>
07 Aug 25	Galenica	Semi-annual report	CHF 86.90	Call	<a href="#">BQCSBU</a>	19 Dec 25	10.59	90.00	0.16	<a href="#">Calls on Galenica</a>
11 Aug 25	Aryzta	Semi-annual report	CHF 75.75	Call	<a href="#">BF8SBU</a>	19 Dec 25	6.94	85.00	0.06	<a href="#">Calls on Aryzta</a>
12 Aug 25	Tecan	Semi-annual report	CHF 158.30	Call	<a href="#">BLNS9U</a>	19 Dec 25	6.51	170.00	0.12	<a href="#">Calls on Tecan</a>
12 Aug 25	Komax	Semi-annual report	CHF 109.20	Call	<a href="#">BDQSNU</a>	19 Dec 25	5.54	120.00	0.13	<a href="#">Calls on Komax</a>
13 Aug 25	Straumann	Semi-annual report	CHF 103.65	Call	<a href="#">UBO8SU</a>	19 Dec 25	7.68	110.00	0.27	<a href="#">Calls on Straumann</a>
14 Aug 25	Swiss Re	Semi-annual report	CHF 149.25	Call	<a href="#">BFMSYU</a>	19 Dec 25	11.41	155.00	0.34	<a href="#">Calls on Swiss Re</a>
				Put	<a href="#">BCHS6U</a>	19 Dec 25	11.06	140.00	0.27	<a href="#">Puts on Swiss Re</a>
14 Aug 25	Swissquote	Semi-annual report	CHF 553.00	Call	<a href="#">BH6S1U</a>	19 Dec 25	7.11	580.00	0.70	<a href="#">Calls on Swissquote</a>
19 Aug 25	Alcon	Semi-annual report	CHF 71.00	Call	<a href="#">B1OSRU</a>	19 Dec 25	9.32	74.00	0.32	<a href="#">Calls on Alcon</a>
				Put	<a href="#">BAYSTU</a>	19 Dec 25	7.45	70.00	0.41	<a href="#">Puts on Alcon</a>
19 Aug 25	Basilea Pharm.	Semi-annual report	CHF 56.60	Call	<a href="#">B7GSKU</a>	19 Dec 25	7.36	60.00	0.12	<a href="#">Calls on Basilea Pharm.</a>

Source: Refinitiv, UBS.

As of: 05 Aug 25. All prices are indicative.

# Company Heartbeats

**International companies** - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Type	Suitable Warrants					
					SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
06 Aug 25	Commerzbank	Semi-annual report	EUR 32.30	Call	<a href="#">SJIBLU</a>	19 Dec 25	6.44	34.00	0.61	<a href="#">Calls on Commerzbank</a>
06 Aug 25	Bayer	Semi-annual report	EUR 27.59	Call	<a href="#">BNKSMU</a>	19 Dec 25	5.98	28.50	0.24	<a href="#">Calls on Bayer</a>
07 Aug 25	Eli Lilly	Semi-annual report	USD 769.00	Call	<a href="#">BBISBU</a>	19 Dec 25	7.54	800.00	0.51	<a href="#">Calls on Eli Lilly</a>
07 Aug 25	Rheinmetall	Semi-annual report	EUR 1,760.00	Call	<a href="#">BCKSCU</a>	19 Dec 25	5.82	1,900.00	1.36	<a href="#">Calls on Rheinmetall</a>
11 Aug 25	Barrick Mining	Semi-annual report	USD 22.18	Call	<a href="#">BTNSMU</a>	19 Dec 25	8.69	23.00	0.25	<a href="#">Calls on Barrick Mining</a>
13 Aug 25	Alibaba	Q1 result	USD 117.50	Call	<a href="#">STUB3U</a>	19 Dec 25	6.88	130.00	0.35	<a href="#">Calls on Alibaba</a>
14 Aug 25	ThyssenKrupp	Q3 result	EUR 9.39	Call	<a href="#">SPGBJU</a>	19 Dec 25	4.74	10.00	1.01	<a href="#">Calls on ThyssenKrupp</a>
27 Aug 25	NVIDIA	Semi-annual report	USD 180.00	Call	<a href="#">BG6SHU</a>	19 Dec 25	7.06	190.00	1.25	<a href="#">Calls on NVIDIA</a>
23 Sep 25	Micron Technology	Annual report	USD 107.77	Call	<a href="#">BSYSIU</a>	19 Dec 25	5.59	120.00	0.81	<a href="#">Calls on Micron Technology</a>
15 Oct 25	Netflix	Q3 result	USD 1,170.99	Call	<a href="#">BGPS4U</a>	20 Mar 26	6.74	1,300.00	0.73	<a href="#">Calls on Netflix</a>
21 Oct 25	Tesla	Q3 result	USD 309.26	Call	<a href="#">BWGSOU</a>	20 Mar 26	4.32	320.00	0.83	<a href="#">Calls on Tesla</a>
22 Oct 25	SAP	Q3 result	EUR 246.15	Call	<a href="#">S3SBBU</a>	20 Mar 26	7.15	260.00	0.31	<a href="#">Calls on SAP</a>

Source: Refinitiv, UBS.

As of: 05 Aug 25. All prices are indicative.

## Disclaimer

This material has been prepared by UBS AG or one of its affiliates ("UBS"). This material is only intended for the distribution permitted under the applicable law. It has not been prepared for the needs of a specific recipient. It is only published for information purposes and does not constitute an offer or an invitation to purchase or sell securities or associated financial instruments ("Instruments"). UBS accepts no liability (either expressly or tacitly) for the completeness or reliability of the information contained in this document, except for the information on UBS AG and its affiliates. The information should not be regarded by the recipients as a substitute for their own judgment. All the opinions contained herein may change without prior notice and contradict the opinions of other business areas of UBS due to the application of different assumptions and criteria. UBS is not obliged to keep the information up to date. UBS, its executives, employees or clients may have or have had a participation in the Instruments and may conclude transactions with them at any time. UBS may maintain or have maintained a relationship with the entities specified in this information. Neither UBS nor its affiliates, executives or employees are liable for losses resulting from the use of this information.

**Structured derivatives do not constitute participation in collective investment schemes. For this reason they do not require approval from the Swiss Financial Market Supervisory Authority (FINMA). As a result, investors are not entitled to the specific investor protection provided by the Swiss Collective Investment Schemes Act (CISA).**

Structured products are complex and involve a high risk. The intrinsic value of the investment instruments depends not only on the performance of the underlying asset, but also on the issuer's creditworthiness (credit risk), which can change over the duration of the product. In relation to any securities, currencies, financial instruments or other assets underlying a transaction to which this material relates, the values may fall as well as rise and past performance is not an indication of future performance. Before entering into any transaction, you should consult your own legal, supervisory, tax, financial and accounting advisors as you consider necessary. You should also make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) at your own discretion and based on your consultation with advisors as you consider necessary. Unless expressly agreed otherwise in writing, UBS does not act as financial advisor or fiduciary in any transaction. The terms and conditions of an investment are subject solely to the detailed provisions, including risk considerations, contained in the relevant product documentation. The product documentation, i.e. the prospectus and the Key Information Document (KID), can be obtained from the website [keyinvest.ch/en.ubs.com](https://keyinvest.ch/en.ubs.com), by entering the relevant security / ISIN. Before you invest in a product, please read the current prospectus and the Key Information Document (KID) carefully and thoroughly. UBS makes no representations or warranties with regard to any information contained herein, which originates from independent sources. This publication may not be copied or reproduced without UBS's prior written permission.

Not for distribution in the United States or to US persons. © UBS 2025. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS. UBS prohibits the forwarding of this information without the approval of UBS.

## Contact

[keyinvest@ubs.com](mailto:keyinvest@ubs.com)

+41 44 239 76 76\*

[ubs.com/keyinvest](https://ubs.com/keyinvest)

\*Please note that calls to numbers marked with \* may be recorded. When you call these numbers, we assume that you consent to this practice.